Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a prominent immunology company pioneering the use of advanced technological innovations to address some of the globe's most challenging infectious diseases. Combining leading scientific expertise with management prowess, Vir Biotechnology focuses on creating solutions for diseases that currently have inadequate or non-existent treatments.
Vir's core business revolves around leveraging breakthroughs in immune programming to manipulate pathogen-host interactions effectively. The company employs a multi-program, multi-platform approach, guided by rigorous science and driven by significant medical needs. Its technology platforms comprise antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).
The company's product pipeline targets severe infectious diseases, including hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB). Vir's revenue streams come from various sources, including collaboration revenue, contract revenue, grant revenue, and license revenue.
Vir's strategy includes internal development, collaborations, and acquisitions, positioning itself as a leader in the biotech space. Notably, Vir's recent collaboration with Brii Biosciences has led to significant advancements in the pursuit of a functional cure for HBV. Through this partnership, they have achieved Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments targeting HBV and chronic hepatitis D virus (HDV) infections.
The company's latest achievements highlight its focus on developing effective therapeutic regimens for chronic HBV infection, a disease affecting over 254 million people globally. With ongoing clinical trials and a commitment to scientific excellence, Vir Biotechnology is at the forefront of transforming the treatment landscape for infectious diseases.
Vir Biotechnology reported first-quarter results as of March 31, 2021, noting total revenues of $2 million, a decrease from $5.7 million in Q1 2020. Research and development expenses surged to $134.9 million, reflecting costs for COVID-19 programs, particularly VIR-7831 and VIR-2218. The net loss widened to $168.9 million, or $1.32 per share, compared to $77.2 million, or $0.71 per share, in the previous year. The company holds $733 million in cash and equivalents, bolstered by a recent equity sale to GSK. Upcoming trials and regulatory submissions highlight ongoing efforts to combat COVID-19.
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its corporate update and financial results for Q1 2021, ending March 31, 2021, on May 6, 2021. The update will be available through a press release after market close on the company's website. Vir Biotechnology focuses on treating serious infectious diseases through innovative immunological technologies, developing candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (NASDAQ: VIR) announces the dosing of its first patient in a Phase 2 clinical trial for chronic hepatitis B (HBV). The trial evaluates the combination of BRII-835 (VIR-2218), an RNA-targeted therapeutic, with BRII-179 (VBI-2601), an HBV immunotherapeutic. This marks the first evaluation of these dual mechanisms in HBV treatment, aiming for a functional cure. The study spans multiple countries, including Australia and China, and is sponsored by Brii Biosciences.
Brii Biosciences, Vir Biotechnology, and VBI Vaccines have commenced a Phase 2 clinical trial for BRII-835 (VIR-2218) and BRII-179 (VBI-2601) aimed at treating chronic hepatitis B virus (HBV) infection. This landmark trial investigates the combination of an siRNA targeting HBV and an HBV immunotherapeutic, marking the first clinical evaluation of this dual-action approach. The study is multi-centered across several countries in Asia and Oceania, focusing on safety and efficacy. Leading experts express optimism about achieving a functional cure for HBV through this innovative combination.
Vir Biotechnology and GSK announced progress in discussions with global regulators for VIR-7831, a monoclonal antibody for treating COVID-19. The European Medicines Agency (EMA) has commenced a review, using interim data from the Phase 3 COMET-ICE trial, which showed an 85% reduction in hospitalization or death. VIR-7831 received a provisional determination from Australia’s TGA, the first for an anti-SARS-CoV-2 monoclonal antibody. An Emergency Use Authorization application is pending with the FDA.
Vir Biotechnology, Inc. (Nasdaq: VIR) published new preclinical research demonstrating how SARS-CoV-2 enters host cells and how auxiliary receptors may impact monoclonal antibodies (mAbs) efficacy. The study identifies three auxiliary receptors that enhance infection, with SIGLEC1 being notably important in severe COVID-19 cases. The research reveals that non-RBM-targeting antibodies, such as VIR-7831 and VIR-7832, show enhanced neutralizing activity compared to RBM-targeting antibodies. These findings support the potential of these investigational mAbs in treating and preventing COVID-19.
Vir Biotechnology announced that CEO George Scangos, Ph.D., will engage in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 8:45 am PT / 11:45 am ET. The session will be accessible via live webcast in the Investors section of the Vir website, with an archived version available for 30 days post-event. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology announced promising results for VIR-7831, an investigational monoclonal antibody targeting SARS-CoV-2. New preclinical data show VIR-7831 maintains its neutralizing activity against the L452R mutation found in the California variant. While the California variant reduces the neutralization potency of plasma from vaccinated individuals, VIR-7831 remains effective, highlighting its potential to combat current and future variants. The company aims to expedite VIR-7831's availability for patients amidst rising variant concerns.
Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced encouraging results from the Phase 2 BLAZE-4 trial, demonstrating a 70% reduction in high viral load for COVID-19 patients treated with bamlanivimab and VIR-7831 compared to placebo. The trial met its primary endpoint with a p-value of <0.001. No COVID-19 related hospitalizations or deaths occurred by day 29 in either treatment arm. Despite these promising data, both drugs are investigational and not yet FDA-approved. Discussions with regulatory bodies are ongoing to expedite availability.
Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced promising topline results from the Phase 2 BLAZE-4 trial, showing that the combination of bamlanivimab and VIR-7831 significantly reduced high viral loads in low-risk COVID-19 patients by 70% at day 7 compared to placebo. No related hospitalizations or deaths occurred by day 29. Preclinical data suggest the combination can combat resistant SARS-CoV-2 variants. An Emergency Use Authorization application for VIR-7831 has been submitted to the FDA, aiming to expedite its availability for COVID-19 treatment.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
What is Vir Biotechnology, Inc.?
What are the main focus areas of Vir Biotechnology?
How does Vir Biotechnology generate its revenue?
What recent achievements has Vir Biotechnology accomplished?
What diseases are targeted by Vir's product pipeline?
What is the significance of Vir's collaboration with Brii Biosciences?
How does Vir's technology platform work?
What are some characteristics of BRII-877 and BRII-835?
How does Vir approach treatment for chronic HBV infection?
What impact does Vir aim to have on global infectious disease treatment?
